35900-16-4 Suppliers

Recommended suppliersmore

35900-16-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 35900-16-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,9,0 and 0 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 35900-16:
(7*3)+(6*5)+(5*9)+(4*0)+(3*0)+(2*1)+(1*6)=104
104 % 10 = 4
So 35900-16-4 is a valid CAS Registry Number.

35900-16-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name	ethyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoate

1.2 Other means of identification

Product number	-
Other names	Prostaglandin E1 ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:35900-16-4 SDS

35900-16-4Upstream product

35900-16-4Downstream Products

35900-16-4Relevant articles and documents

USE OF PROSTAGLANDIN E1 METHYL ESTER IN PREPARING VASODILATOR DRUG

-

Paragraph 0019-0021, (2021/10/07)

Provided in the present invention is a use of prostaglandin E1 methyl ester in preparing a vasodilator drug. The structural formula of the prostaglandin E1 methyl ester is represented by formula (I) The vasodilator drug is a drug used to treat the following diseases: a microcirculatory disorder, coronary heart disease, angina, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma.

Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration

-

, (2008/06/13)

The invention describes prostaglandin E1 derivatives as pharmacologically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 35900-16-4

CAS

35900-16-4